Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 3109       
REVIEW ARTICLE
Year : 2021  |  Volume : 153  |  Issue : 1  |  Page : 64-85

Use of convalescent plasma for COVID-19 in India: A review & practical guidelines


1 Department of Internal Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India
2 Department of Anaesthesia & Intensive Care, Postgraduate Institute of Medical Education & Research, Chandigarh, India
3 Department of Transfusion Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India
4 Department of Endocrinology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
5 Department of Virology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
6 Clinical Trial & Health System Research Unit, Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India

Correspondence Address:
Dr. Pankaj Malhotra
Department of Internal Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmr.IJMR_3092_20

Rights and Permissions

Convalescent plasma (CP) therapy is one of the promising therapies being tried for COVID-19 patients. This passive immunity mode involves separating preformed antibodies against SARS-CoV-2 from a recently recovered COVID-19 patient and infusing it into a patient with active disease or an exposed individual for prophylaxis. Its advantages include ease of production, rapid deployment, specificity against the target infectious agent, and scalability. In the current pandemic, it has been used on a large scale across the globe and also in India. However, unequivocal proof of efficacy and effectiveness in COVID-19 is still not available. Various CP therapy parameters such as donor selection, antibody quantification, timing of use, and dosing need to be considered before its use. The current review attempts to summarize the available evidence and provide recommendations for setting up CP protocols in clinical and research settings.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed410    
    Printed2    
    Emailed0    
    PDF Downloaded132    
    Comments [Add]    

Recommend this journal